KELLY HEILMAN: Open Payments
NPI 1316497662 · GLASTONBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$930 in 41 payments from 12 companies in 2025. Trend: 2023 $1,228 · 2024 $1,200 · 2025 $930
Food & beverage: $930
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 10 | $310 |
| GlaxoSmithKline, LLC. | 14 | $173 |
| AstraZeneca Pharmaceuticals LP | 6 | $159 |
| Optinose US, Inc. | 1 | $78 |
| GENZYME CORPORATION | 3 | $51 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| CSL Behring | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
Products named: DUPIXENT, TRELEGY ELLIPTA, XHANCE, TEZSPIRE, NUCALA, AIRSUPRA, NEFFY, Andembry.
Industry payments across CT — which companies pay providers there.
